<DOC>
	<DOC>NCT00705367</DOC>
	<brief_summary>The purpose of this study is to determine whether abatacept at a dose 30 mg/kg via intravenous infusion is safe and well tolerated in the treatment of lupus nephritis in mainland Chinese subjects with systemic lupus erythematosus (SLE)</brief_summary>
	<brief_title>Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg</brief_title>
	<detailed_description />
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Men and women, at least 18 years of age, with a diagnosis of systemic lupus erythematosus (SLE) and with lupus nephritis currently stable for the last 3 months without change in treatment for lupus nephritis Stable renal disease No flaring of other organ systems in a minimum of the last 3 months Unstable lupus nephritis and serum creatinine &gt;3 mg/dL Progressive renal failure, end stage renal disease, or renal transplant requiring continuous dialysis Severe unstable, refractory, or progressive SLE History of cancer Participants at risk for tuberculosis Autoimmune disease other than SLE as main diagnosis Human immunodeficiency virus or herpes zoster infection HepatitisB surface antigenpositive or hepatitis C antibodypositive participants</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>